Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815993 | 0.82 | LPL (0.46) | LPLLIPGESR2F11ENPP2 | |
| SCHEMBL840164 | 0.77 | HDAC6 (0.50) | HDAC6HDAC1HDAC2HDAC8ENPP2 | |
| SCHEMBL7696987 | 0.77 | HDAC6 (0.56) | HDAC6HDAC1HDAC2HDAC8ENPP2 | |
| SCHEMBL14659551 | 0.73 | L3MBTL1 (0.55) | LPLLIPGESR2F11 | |
| SCHEMBL18954100 | 0.73 | L3MBTL1 (0.51) | LPLLIPGESR2F11 | |
| SCHEMBL16880416 | 0.71 | POLB (0.54) | LPLLIPGESR2F11 | |
| SCHEMBL2239353 | 0.71 | LPL (0.44) | LPLLIPGESR2F11 | |
| SCHEMBL23242449 | 0.70 | LPL (0.43) | LPLLIPGESR2F11 | |
| SCHEMBL22655382 | 0.69 | BMPR1B (0.44) | LPLLIPG | |
| SCHEMBL23242460 | 0.69 | LIPG (0.43) | LPLLIPGESR2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| EP-2373639-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063666-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | OPRM1, OR10J3, OPRD1 | LPL 4876/4885LIPG 4885/4885HDAC6 2041/4885 |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | LPL 4879/4885LIPG 4884/4885HDAC6 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.